Why BioScrip (BIOS) Stock Is Surging Today

NEW YORK (TheStreet) -- BioScrip  (BIOS) surged Friday after the pharmaceutical solutions company reported mixed first-quarter results and issued guidance that surpassed analysts' expectations.

The company reported a loss of 13 cents a share, which was wider than the Capital IQ Consensus Estimate of a loss of 2 cents a share. But revenues increased 20.3% year over year to $239.6 million to surpass the $221.69 consensus estimate.

BioScrip also issued full-year revenue guidance for 2014 in the range of $940 million to $980 million, which beat analysts' estimate of $922.39 million.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 15.6% to $7.04 at 3:17 p.m.

BIOS Chart

BIOS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Stick to Small, Fast Trades Until the Fed's out of the Way

These 5 Stocks Under $10 Could Light Up Soon

5 Stocks Insiders Love Right Now

BioScrip (BIOS) Stock: Weak On High Volume Today

5 Stocks Under $10 Set to Soar